| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Total revenue | 351 | - | ||
| Research and development expenses | 12,616 | 12,939 | ||
| General and administrative expenses | 9,476 | 10,253 | ||
| Manufacturing services | 736 | 1,689 | ||
| Total operating expenses | 22,828 | 24,881 | ||
| Interest expense | - | 0 | ||
| Loss from operations | -22,477 | -24,881 | ||
| Gain on sale of vowst business | 27,222 | 185 | ||
| Interest income | 618 | 546 | ||
| Other income (expense) | 2,841 | 4,295 | ||
| Total other income (expense), net | 30,681 | 5,026 | ||
| Net income (loss) from continuing operations | 8,204 | -19,855 | ||
| Net income from discontinued operations, net of tax | 0 | 0 | ||
| Net income (loss) | 8,204 | -19,855 | ||
| Net loss per share attributable to common stockholders - basic | 0.94 | -2.27 | ||
| Net loss per share attributable to common stockholders - diluted | 0.94 | -2.27 | ||
| Weighted average number of shares outstanding, diluted | 8,771,519 | 8,743,733 | ||
| Weighted-average shares outstanding - basic | 8,758,692 | 8,743,733 | ||
Seres Therapeutics, Inc. (MCRB)
Seres Therapeutics, Inc. (MCRB)